PMV Pharmaceuticals, Inc.

Listed Company

PMVPCIK 0001699382NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-77.74M

Total Assets

$116.56M

Equity

$104.71M

Shares Out

53.33M

Op. Cash Flow

$-73.58M

PMVP$1.33−0.75% · past yearDBEQ Basic

Daily closing prices

Business

PMV Pharmaceuticals, Inc. is a precision oncology company developing selective small molecule therapies that structurally correct mutant p53 proteins to restore wild-type tumor suppressor function. Its main product candidate is rezatapopt, an orally available small molecule targeting the p53 Y220C mutation, and it operates a pipeline of additional oral small molecule programs targeting other p53 mutations or p53-related cancers. Key business activities include discovery, lead optimization, IND-enabling studies and clinical development (the PYNNACLE Phase 1/2 program) and companion diagnostic collaborations. PMV conducts global clinical trials and collaborations across the U.S., U.K., Europe and Asia-Pacific and relies on third-party manufacturers and diagnostic partners for development and testing.

Summary from filing dated 2025-03-03

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	70	59	56	52	36
General and administrative	16	27	24	25	22
Total operating expenses	86	85	80	77	58
Loss from operations	−86	−85	−80	−77	−58
Interest income, net	6	11	11	4	449,000
Other (expense) income, net	−45,000	−16,000	3,000	87,000	21,000
Total other income	6	11	11	4	470,000
Loss before provision (benefit) for income taxes	−80	−75	−69	−73	−58
Provision (benefit) for income taxes	−2	−16	2,000	−9,000	23,000
Net loss	−78	−59	−69	−73	−58
Unrealized (loss) gain on available for sale investments, net of tax	−63,000	−50,000	635,000	−367,000	−78,000
Foreign currency translation gain (loss) gain	8,000	−35,000	34,000	—	—
Total other comprehensive (loss) income	−55,000	−85,000	669,000	−367,000	−78,000
Total Comprehensive loss	−78	−59	−68	−74	−58
Net loss per share - basic	−1.48	−1.14	−1.44	−1.61	−1.28
Net loss per share - diluted	−1.48	−1.14	−1.44	−1.61	−1.28
Weighted-average common shares outstanding - basic	53	52	48	46	45
Weighted-average common shares outstanding - diluted	53	52	48	46	45

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	38	41	38	108	172
Marketable securities, current	75	129	165	133	125
Prepaid expenses and other current assets	2	6	4	5	3
Total current assets	115	176	207	247	301
Property and equipment, net	237,000	409,000	11	11	3
Marketable securities, noncurrent	0	14	26	2	17
Right-of-use assets	801,000	1	8	10	10
Other assets	297,000	235,000	190,000	313,000	221,000
Total assets	117	191	252	270	332
Accounts payable	3	7	3	3	3
Accrued expenses	8	7	10	7	9
Operating lease liabilities, current	403,000	352,000	852,000	528,000	403,000
Total current liabilities	11	14	14	11	12
Operating lease liabilities, noncurrent	435,000	838,000	12	13	11
Total liabilities	12	15	26	24	23
Commitments and contingencies (see Note 6)	—	—	—	—	—
Preferred stock, $0.00001 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024. No shares issued or outstanding as of December 31, 2025 and December 31, 2024.	—	—	—	—	—
Common stock, $0.00001 par value, 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 53,331,766 and 51,935,134 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively.	—	—	—	—	—
Additional paid-in capital	551	545	535	488	476
Accumulated deficit	−446	−369	−310	−241	−168
Accumulated other comprehensive income	84,000	139,000	224,000	−445,000	−78,000
Total stockholders' equity	105	176	226	246	309
Total liabilities and stockholders equity	117	191	252	270	332

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−78	−59	−69	−73	−58
Stock-based compensation expense	6	9	12	10	5
Depreciation	133,000	1	1	315,000	307,000
Accretion of discounts on marketable securities	−3	−5	−5	−628,000	550,000
Non-cash lease income	−10,000	−248,000	−370,000	335,000	974,000
Loss on termination of lease, net	—	5	—	—	—
Loss on sales and disposals of fixed assets, net	37,000	62,000	—	—	—
Other, net	−62,000	−44,000	—	−92,000	−19,000
Prepaid expenses and other assets	4	−3	2	−2	38,000
Operating lease right-of-use assets and liabilities	—	241,000	837,000	—	—
Accounts payable	−3	3	235,000	−389,000	191,000
Accrued expenses	418,000	−3	3	−1	4
Net cash used in operating activities	−74	−51	−56	−64	−47
Purchases of property and equipment	−29,000	−655,000	−962,000	−8	−1
Proceeds from sale of property and equipment	31,000	251,000	—	—	—
Purchases of marketable securities	−88	−148	−221	−229	−257
Maturities of marketable securities	158	202	171	236	115
Net cash provided by investing activities	70	53	−51	−1	−144
Issuance of common stock, net of issuance costs	—	—	35	—	—
Proceeds from the exercise of stock options and common stock issued under the 2020 EIP	505,000	313,000	456,000	958,000	2
Net cash provided by financing activities	505,000	313,000	36	958,000	2
Impact of exchange rates on cash, cash equivalents, and restricted cash	7,000	−35,000	34,000	—	—
Net (decrease) increase in cash and cash equivalents	−3	2	−71	−64	−188
Accrued purchases of property and equipment	—	—	6,000	196,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is PMV Pharmaceuticals, Inc.'s CIK number?

PMV Pharmaceuticals, Inc.'s SEC CIK number is 0001699382 (1699382). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find PMV Pharmaceuticals, Inc.'s SEC filings?

All of PMV Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did PMV Pharmaceuticals, Inc. last report earnings?

PMV Pharmaceuticals, Inc. (PMVP) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-218225). This is PMV Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is PMV Pharmaceuticals, Inc.'s most recent earnings 8-K?

PMV Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-218225. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View PMV Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →